Evaluation & Management of Fibrotic Interstitial Lung Diseases

Program Description

This video-based learning activity provides updates by experts about diagnosis and management, as well as therapeutic options for specific types of Interstitial lung diseases.

There are five videos of expert presenters. To see the session titles, review the Objectives below. To learn about the speakers, review the Faculty tab.

This learning activity includes recordings from the Adult Pulmonary Core series presented at the 2022 ATS International Conference. The Core supports clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements. The ATS Pulmonary Clinical Core Curriculum focuses on a 3-year content cycle of key topics in Pulmonary Medicine. This symposium is intended to help clinicians stay up-to-date with important information relevant to their medical practices, and to provide an opportunity for clinicians to evaluate their individual knowledge and skills while earning MOC Medical Knowledge points.

Target Audience

This session is intended for clinicians who care for patients with interstitial lung disease, including practicing internists, subspecialists, registered nurses and advanced practice nurses in pulmonary, critical care, and sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification.

Learning Objectives

The objectives are sorted by session video.

Diagnostic Approach to Interstitial Lung Disease (Erica Farrand, MD)

• Discuss the importance of proper classification of ILD
• Discuss non-invasive studies used to diagnose ILD, including emerging biomarkers 
• Understand when and how invasive studies are applied in making an ILD diagnosis
• Define the features of a multidisciplinary conference and its impact on ILD diagnosis

Granulomatous Lung Diseases (Bridget Collins, MD)

• Develop a framework for the evaluation of granulomatous lung disease in clinical practice
• Compare and contrast clinical features of the most common noninfectious granulomatous lung diseases 
• Discuss diagnostic approach to common noninfectious granulomatous lung diseases 
• Describe variable management and prognosis in granulomatous lung disease 
• Analyze uncertainties in granulomatous lung disease that may influence outcomes 

Pulmonary Manifestations of Autoimmune Disease (Leticia Kawano-Dourado, MD)

• Describe common and uncommon pulmonary manifestations of autoimmune diseases 
• List differential diagnoses in the context of a patient with autoimmune disease and pulmonary symptoms/signs 
• Manage the pulmonary manifestations of autoimmune diseases based on the most recent medical evidence 

Idiopathic Pulmonary Fibrosis (Ayodeji Adegunsoye, MD, MS)

• Identify essential components in the initial evaluation of patients with IPF
• Recognize risk factors for disease progression and highlight strategies for monitoring IPF over time
• Describe the current approach to timing of anti-fibrotic therapy and lung transplantation evaluation in IPF management

Therapeutic Options in Progressive Fibrotic Lung Disease (Robert Hallowell, MD)

• Discuss the mechanism of action, efficacy, and side effect profile for both pirfenidone and nintedanib. 
• Identify diseases in which the presence of progressive fibrosing interstitial lung disease (PF-ILD) may warrant the use of anti-fibrotic therapy.  
• Recognize emerging antifibrotic therapies and their potential mechanisms of action